Advertisement

Enhancement of Antibody Response to an Antigonadotropin Vaccine by use of Adjuvants

  • H. A. Nash
  • C. C. Chang
  • Y. Y. Tsong
Part of the Reproductive Biology book series (RBIO)

Abstract

Initial clinical trials of an antipregnancy vaccine consisting of the β-subunit of human chorionic gonadotropin linked to tetanus toxoid (β-hCG-TT) and adsorbed on Al (OH)3 resulted in low and short-lived antibody titers in some of the women studied (1,2). It was therefore judged necessary to find ways to enhance the antibody response. Approaches explored included the use of other adjuvants to supplement the aluminum hydroxide and the use of modified vehicles. The effectiveness of these expedients was evaluated by vaccinating rabbits and measuring the concentration in serum of antibodies capable of binding labeled hCG. In selected instances, the ability of the antiserum to inhibit stimulation by hCG of uterine growth in immature rats was also measured. Some of the findings have been reported in earlier publications (3,4). They are summarized and extended in the present review.

Keywords

Human Chorionic Gonadotropin Tetanus Toxoid Sorbitan monoOleate Aluminum Potassium Sulfate Streptococcal Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nash, H., Talwar, G. P., Segal, S., Luukkainen, T., Johansson, E.D.B., Vasquez, J., Coutinho, E., and Sundaram, K. Observations on the antigenicity and clinical effects of a candidate antipregnancy vaccine: β-subunit of human chorionic gonadotropin linked to tetanus toxoid. Fertil. Steril. 34: 328 (1980).PubMedGoogle Scholar
  2. 2.
    Shahani, S.M., Kulkarni, P.P., Patel, K.L., Salahuddin, M., Das, C., and Talwar, G.P. Clinical and immunological responses with Pr-β-hCG-TT vaccine. Contraception 25: 421 (1982).PubMedCrossRefGoogle Scholar
  3. 3.
    Nash, H.A., Chang, C.C., and Tsong, Y.Y. Formulation of a potential antipregnancy vaccine based on the β-subunit of human chorionic gonadotropin (β-hCG). Use of compounds of the muramyl dipeptide (MDP) family as adjuvants. J. Reprod. Immunol. 7:151 (1985).PubMedCrossRefGoogle Scholar
  4. 4.
    Chang, C.C., Tsong, Y.Y., and Nash, H.A. Formulation of a potential antipregnancy vaccine based on the β-subunit of human chorionic gonadotropin (β-hCG). III. Evaluation of various vehicles and adjuvants. J. Reprod. Immunol. 7:163 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    Tsong, Y.Y., Chang, C.C., and Nash, H.A. Formulation of a potential antipregnancy vaccine based on the β-subunit of human chorionic gonadotropin (β-hCG). I. Alternative macrcmolecular carriers. J. Reprod. Immunol. 7:139 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    Siddiqui, W.A., Taylor, D.W., Kan, S.-C., Kramer, K., Richmond-Crum, S.M., Kotani, S., Shiba, T., and Kusunoto, S. Vaccination of experimental monkeys against Plasmodium falciparum; a possible safe adjuvant. Science 201:1237 (1978).PubMedCrossRefGoogle Scholar
  7. 7.
    Audibert, F., Parant, M., Damais, C., Lefrancier, P., Derrien, M., Choay, J., and Chedid, L. Dissociation of immunostimulant activities of muranyl dipeptide (MDP) by linking amino acids or peptides to the glutaminyl residue. Biochem. Biophys. Res. Commun. 96:915 (1980).PubMedCrossRefGoogle Scholar
  8. 8.
    Jolivet, M., Sache, E., and Audibert, F. Biological studies of lipophilic MDP derivatives incorporated in liposomes. Immunol. Commun. 10:511 (1981).PubMedGoogle Scholar
  9. 9.
    Hunter, R., Strickland, F., and Kezdy, F. The adjuvant activity of nonionic block polymer surfactants. I. The role of lydrophilelipophile balance. J. Immunol. 127:1244 (1981).PubMedGoogle Scholar
  10. 10.
    Snippe, H., DeReuver, M. J., Strickland, F., Willers, J.M.N., and Hunter, R.L. Adjuvant effect of nonionic block surfactants in humoral and cellular immunity. Int. Arch. Allergy Appl. Immunol. 65:390 (1981).PubMedCrossRefGoogle Scholar
  11. 11.
    Elin, R.J., Wolff, S.M., McAdam, K.P.W.J, Chedid, L., Audibert, F., Barnard, C., and Aberling, F. Properties of reference Eschrechia coli endotoxin and its phthalylated derivative in humans. J. Infect. Dis. 144: 329 (1981).PubMedCrossRefGoogle Scholar
  12. 12.
    Niblack, J.F., Otterness, I.G., Hemsworth, G.R., Wolff, J.S. III, Hoffman, W.W., and Kraska, A.R. CP-20,961: A structurally novel synthetic adjuvant. J. Reticuloendothel. Soc. 26: 655 (1979).PubMedGoogle Scholar
  13. 13.
    Anderson, A.O. and Reynolds, J.A. Adjuvant effects of the lipid amine CP 20,961. J. Reticuloendothel. Soc. 26: 667 (1979).PubMedGoogle Scholar
  14. 14.
    Hilgers, A.Th.H, Snippe, H., Jansze, M., and Willers, J.M.N. Immuno-modulating properties of two synthetic adjuvants: Dependence on type of antigen, dose and time of administration. Cellular Immunol. 86: 393 (1984).CrossRefGoogle Scholar
  15. 15.
    Friedman, H. Immuncmodulation by small molecular weight bacterial products. Adv. Exptl. Med. Biol. 166: 199 (1983).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • H. A. Nash
    • 1
  • C. C. Chang
    • 1
  • Y. Y. Tsong
    • 1
  1. 1.Center for Biomedical ResearchThe Population CouncilNew YorkUSA

Personalised recommendations